Avatrombopag

Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.


Cat. No.: EX-A6599	Purity: >99%

	Chemical structure of Avatrombopag

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	485	In-stock
500mg	600	In-stock
1g	800	In-stock
5g	1650	In-stock
10g	2500	In-stock
20g	3850	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	AKR-501
CAS No.	570406-98-3
Purity	>99%
Formula	C29H34Cl2N6O3S2
Mol Weight	649.655
Color	White to light yellow
State	solid powder
Solubility	Soluble in DMSO 8.33 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20℃ 3 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Fukushima-Shintani M, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247-254. [2]. Xu H, et al. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019 Sep;12(9):859-865. [3]. Nomoto M, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952-960.
CoA	CoA of Avatrombopag


		Search